Retatrutide, developed by Soma Chems , represents a promising development in weight regulation. This dual-action compound combines incretin signaling activity with GIP receptor engagement, showing substantial results in clinical studies for weight loss . Researchers believe the drug could offer a different solution for patients struggling with obes